Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Greaves, 1995, Treatment of psoriasis, N Engl J Med, 322, 581, 10.1056/NEJM199503023320907

Feldman, 1997, The economic impact of psoriasis increases with psoriasis severity, J Am Acad Dermatol, 37, 564, 10.1016/S0190-9622(97)70172-5

Ellis, 1991, Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial, N Engl J Med, 324, 277, 10.1056/NEJM199101313240501

Gottlieb, 1998, Psoriasis, Dis Manage Clin Outcomes, 1, 195, 10.1016/S1088-3371(98)00025-4

Bos, 1999, The pathogenesis of psoriasis: immunological facts and speculations, Immunol Today, 1, 40, 10.1016/S0167-5699(98)01381-4

Gottlieb, 1997, Immunopathogenesis of psoriasis, Arch Dermatol, 133, 781, 10.1001/archderm.133.6.781

Baker, 1992, The immunology of psoriasis, Br J Dermatol, 126, 1, 10.1111/j.1365-2133.1992.tb08394.x

Ortonne, 1996, Aetiology and pathogenesis of psoriasis, Br J Dermatol, 135, 1, 10.1111/j.1365-2133.1996.tb15660.x

Gottlieb AB. Psoriasis: immunopathology and immunomodulation. Dermatol Clin North Am (in press)

Ettehadi, 1994, Elevated tumour necrosis factor-alpha biological activity in psoriatic skin lesions, Clin Exp Immunol, 96, 146, 10.1111/j.1365-2249.1994.tb06244.x

Barnes, 1997, Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory disease, N Engl J Med, 336, 1066, 10.1056/NEJM199704103361506

Knight, 1993, Construction and initial characterization of a mouse-human chimeric anti-TNF antibody, Mol Immunol, 20, 1443, 10.1016/0161-5890(93)90106-L

Oh, 2000, Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions, J Am Acad Dermatol, 42, 829, 10.1067/mjd.2000.105948

Fredrikkson, 1978, Severe psoriasis: oral therapy with a new retinoid, Dermatologica, 157, 238, 10.1159/000250839

Gottlieb, 2000, Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis, J Am Acad Dermatol, 42, 428, 10.1016/S0190-9622(00)90214-7

Gottlieb, 2000, Results of a single-dose, dose-escalating trial of anti-B7. 1 monoclonal antibody (IDEC-114) in patients with psoriasis, J Invest Dermatol, 114, 840

Magilavy, 1999, Immunopharmacologic effects of Amevive (LFA3TIP) in chronic plaque psoriasis: selectivity for peripheral memory-effector (CD45RO+) over Naïve (CD45RA+) T cells: AMEVIVE Clinical Study Group, Br J Dermatol, 141, 990

Krueger, 2000, Successful in vivo blockage of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis, J Am Acad Dermatol, 43, 448, 10.1067/mjd.2000.106515

Abrams, 2000, Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathway of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells, J Exp Med, 192, 681, 10.1084/jem.192.5.681

Asadullah, 1998, IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach, J Clin Invest, 101, 783, 10.1172/JCI1476

Trepicchio, 1999, IL-11 is an immunemodulatory cytokine which downregulates IL-12, Type 1 cytokines, and multiple inflammation-associated genes in patients with psoriasis, J Invest Dermatol, 112, 598

Mease, 2000, Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial, Lancet, 356, 383, 10.1016/S0140-6736(00)02530-7

Scallon, 1995, Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions, Cytokine, 7, 251, 10.1006/cyto.1995.0029

Barone, 1999, Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion, Arthritis Rheum, 42, S90

Scallon, 2000, New comparisons of two types of TNFα antagonists approved for rheumatoid arthritis, Arthritis Rheum, 43, S226

Wakefield, 1991, Tumor necrosis factor, J Am Acad Dermatol, 24, 675, 10.1016/0190-9622(91)70102-8

Kimber, 2000, Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization, Br J Dermatol, 142, 401, 10.1046/j.1365-2133.2000.03349.x

Tak, 1996, Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis, Arthritis Rheum, 39, 1077, 10.1002/art.1780390702

Baeten, 2000, Effect of TNFα blockade on synovial histology in spondyloarthropathy, Arthritis Rheum, 43

Schluter, 2000, Very rapid antiinflammatory effect of anti-TNF-α (RemicadeTM) in Crohn's disease as assessed by 99MTC-WBC-scintigraphy, Gastroenterology, 118

Taylor, 2000, Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis, Arthritis Rheum, 43, 38, 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L

Baert, 1999, Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation of Crohn's ileocolitis, Gastroenterology, 116, 22, 10.1016/S0016-5085(99)70224-6

Nikolaus, 2000, Increased peripheral production of TNF-α and mucosal levels of activated NFαB predict relapse after treatment with infliximab in patients with Crohn's disease, Gastroenterology, 118

Geboes, 2000, Decreased mucosal lymphocyte proliferation following treatment with infliximab in Crohn's disease, Gastroenterology, 118